No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - AIM-listed biotech Physiomics has announced a new contract with client Numab Therapeutics to help development activities for the latter's oncology pipeline.
The contract, which is set to begin this month and last sometime in the third quarter, will see Physiomics develop a so-called mechanistic pharmacokinetic-pharmacodynamic modelling framework to support Numab in its proof-of-concept work for a new programme.
Physiomics will interpret data, optimise experimental design and development strategy, and inform key go/no-go decision-making for Numab, it said.
"We are thrilled to extend our collaboration with Numab Therapeutics to provide insights that can support robust proof-of-concept decision-making for this early oncology programme," said Physiomics chief executive Peter Sargent.
The stock was up 1.8% at 0.51p by 1456 BST.
See the latest RNS on Investegate.
No financial details regarding the contract were published.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.